help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LAWRENCE, M.
Right arrow Articles by SHAH, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LAWRENCE, M.
Right arrow Articles by SHAH, T.

Am. J. Respir. Crit. Care Med., Volume 156, Number 3, September 1997, 744-751

Efficacy of Inhaled Fluticasone Propionate in Asthma Results from Topical and Not from Systemic Activity

MICHAEL LAWRENCE, JAMES WOLFE, D. ROBERT WEBB, PAUL CHERVINSKY, DONALD KELLERMAN, JOHN P. SCHAUMBERG, and TUSHAR SHAH

Asthma and Allergy Physicians, Taunton, Massachusetts; Allergy and Asthma Associates of Santa Clara Valley, San Jose, California; Allergy and Asthma Center, North Dartmouth, Massachusetts; Glaxo Wellcome Inc., Research Triangle Park, North Carolina

The objective of this study was to determine whether the therapeutic benefits of inhaled fluticasone propionate are mediated through topical or systemic effects. Two hundred seventy-four patients with asthma receiving beclomethasone dipropionate or triamcinolone acetonide during a 2-wk, single-blind, run-in period were randomized to inhaled fluticasone propionate powder 100 or 500 µg twice daily, oral fluticasone propionate 20 mg once daily, or placebo during a 6-wk treatment period. Patients receiving inhaled fluticasone propionate had a significantly greater probability of remaining in the study over time compared with patients receiving oral fluticasone propionate or placebo (p = 0.001). FEV1 and PEF rates at end point were significantly higher with inhaled fluticasone propionate treatment regimens than with oral fluticasone propionate (with the exception of PEF rates for inhaled fluticasone propionate 100 µg) or placebo treatments (p =< 0.004). Systemic exposure to fluticasone propionate as assessed by trough plasma concentrations and/or 12-hr plasma concentration area under the curve analyses (AUC12) was higher with the oral fluticasone propionate than with the two inhaled fluticasone propionate treatment groups. The results of this study suggest that the therapeutic benefits of inhaled fluticasone propionate are mediated through topical effects in the lungs and not through systemic effects.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
C. M. Roller, G. Zhang, R. G. Troedson, C. L. Leach, P. N. Le Souef, and S. G. Devadason
Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children
Eur. Respir. J., February 1, 2007; 29(2): 299 - 306.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
G. L. Colice
Categorizing Asthma Severity: An Overview of National Guidelines
Clin. Med. Res., August 1, 2004; 2(3): 155 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
B. Luijk, R.D. Kempsford, A.M. Wright, P. Zanen, and J-W.J. Lammers
Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction
Eur. Respir. J., April 1, 2004; 23(4): 559 - 564.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M Masoli, M Weatherall, S Holt, and R Beasley
Clinical dose-response relationship of fluticasone propionate in adults with asthma
Thorax, January 1, 2004; 59(1): 16 - 20.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
E. O. Meltzer, R. F. Lockey, B. F. Friedman, C. Kalberg, S. Goode-Sellers, S. Srebro, L. Edwards, K. Rickard, and Fluticasone Propionate Clinical Research Study Gro
Efficacy and Safety of Low-Dose Fluticasone Propionate Compared With Montelukast for Maintenance Treatment of Persistent Asthma
Mayo Clin. Proc., May 1, 2002; 77(5): 437 - 445.
[Abstract] [PDF]

Home page
 ThoraxHome page
R J Meijer, D S Postma, and H A M Kerstjens
Conventional RIA underestimates cortisol suppression in the presence of prednisolone
Thorax, April 1, 2002; 57(4): 374 - 374.
[Full Text] [PDF]

Home page
 BMJHome page
S. Holt, A. Suder, M. Weatherall, S. Cheng, P. Shirtcliffe, R. Beasley, and A. Herxheimer
Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis Commentary: Dosage needs systematic and critical review
BMJ, August 4, 2001; 323(7307): 253 - 253.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. J. Lipworth, R. A. Nathan, and R. ZuWallack
Fluticasone and Cortisol Measurements
Chest, March 1, 2001; 119(3): 984 - 985.
[Full Text] [PDF]

Home page
 ThoraxHome page
R J Meijer, H A M Kerstjens, L R Arends, H F Kauffman, G H Koëter, and D S Postma
Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma
Thorax, October 1, 1999; 54(10): 894 - 899.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society 		  CCM abstracts